Lancet Oncol:空气污染会增高肺癌发病风险

2013-07-11 echo1166 dxy

近期,在《柳叶刀肿瘤学》上发表的一项研究的结果指出,即使空气污染的程度低于欧盟所规定的标准,长期暴露在这些特定的空气污染中仍然会增加肺癌(尤其是肺腺癌)的发生风险。 来自日本冈山大学环境和生命科学研究生院的Takashi Yorifuji 和广岛大学的Saori Kashima在述评中指出:“在现阶段,我们需要将空气污染(甚至是现阶段的浓度)列为肺癌的致病因素,并且我们也需要认识到空气污

近期,在《柳叶刀肿瘤学》上发表的一项研究的结果指出,即使空气污染的程度低于欧盟所规定的标准,长期暴露在这些特定的空气污染中仍然会增加肺癌(尤其是肺腺癌)的发生风险。 

来自日本冈山大学环境和生命科学研究生院的Takashi Yorifuji 和广岛大学的Saori Kashima在述评中指出:“在现阶段,我们需要将空气污染(甚至是现阶段的浓度)列为肺癌的致病因素,并且我们也需要认识到空气污染对公众健康造成较大的影响。

来自丹麦肿瘤协会研究中心的Ole Raaschou-Nielsen带领了一个欧洲研究团队来评价长期暴露于氮氧化物和颗粒物质(直径小于2.5微米——PM 2.5和直径小于10微米——PM10)的环境中会对肺癌发病风险造成怎样的影响。颗粒物质空气污染源包括来自于交通、工业和家庭供暖所带来的污染。

研究者应用来自于欧洲空气污染效应队列研究(ESCAPE)的相关数据,同时与Utrecht大学的研究者合作,对在欧洲9个国家进行的17个队列研究进行了荟萃分析(这些研究共纳入了约313000名受试者)。

研究者采用土地利用回归模型来估计在家庭中空气污染的浓度。在国立和地区肿瘤注册机构追踪新确诊为肺癌的受试者,并且采用统计模型来区分空气污染和其他因素(如吸烟、饮食和职业等因素)对肺癌发病所产生的影响。

在进行了平均13年的随访之后,在上述的受试者中有2095人演变成了肺癌患者。

该荟萃分析发现,PM 2.5污染每增加5微克每立方米,肺癌的发病风险增加18%;而PM 10污染每增加5微克每立方米,肺癌的发病风险增加22%,并且上述污染对于腺癌的发病影响更大。研究者没有观察到氮氧化物和肺癌发病风险增高之间存在相关性。

据作者指出,“即使PM10和PM2.5的值低于欧盟空气质量限制的标准(PM10为40 μg/m3而PM2.5为25 μg/m3),但是颗粒物质所造成的空气污染和肺癌发病风险之间所存在的联系仍持续存在。我们并没有发现存在与无风险相对应的阈值,研究结果向我们描绘的蓝图是——越多越差,越少越好。”


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799776, encodeId=8bf51e99776c2, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Sep 27 05:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864461, encodeId=f2f71864461bc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 23 20:05:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827585, encodeId=606d182e58558, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 20 14:05:00 CST 2014, time=2014-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472420, encodeId=dbd114e242054, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561550, encodeId=e92e15615506d, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567559, encodeId=2f33156e5592e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799776, encodeId=8bf51e99776c2, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Sep 27 05:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864461, encodeId=f2f71864461bc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 23 20:05:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827585, encodeId=606d182e58558, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 20 14:05:00 CST 2014, time=2014-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472420, encodeId=dbd114e242054, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561550, encodeId=e92e15615506d, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567559, encodeId=2f33156e5592e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=)]
    2014-05-23 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799776, encodeId=8bf51e99776c2, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Sep 27 05:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864461, encodeId=f2f71864461bc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 23 20:05:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827585, encodeId=606d182e58558, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 20 14:05:00 CST 2014, time=2014-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472420, encodeId=dbd114e242054, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561550, encodeId=e92e15615506d, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567559, encodeId=2f33156e5592e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=)]
    2014-01-20 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799776, encodeId=8bf51e99776c2, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Sep 27 05:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864461, encodeId=f2f71864461bc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 23 20:05:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827585, encodeId=606d182e58558, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 20 14:05:00 CST 2014, time=2014-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472420, encodeId=dbd114e242054, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561550, encodeId=e92e15615506d, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567559, encodeId=2f33156e5592e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799776, encodeId=8bf51e99776c2, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Sep 27 05:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864461, encodeId=f2f71864461bc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 23 20:05:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827585, encodeId=606d182e58558, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 20 14:05:00 CST 2014, time=2014-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472420, encodeId=dbd114e242054, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561550, encodeId=e92e15615506d, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567559, encodeId=2f33156e5592e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=)]
    2013-07-13 liuxiaona
  6. [GetPortalCommentsPageByObjectIdResponse(id=1799776, encodeId=8bf51e99776c2, content=<a href='/topic/show?id=9e3fe127909' target=_blank style='color:#2F92EE;'>#癌发病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71279, encryptionId=9e3fe127909, topicName=癌发病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2c92500045, createdName=12498636m49(暂无昵称), createdTime=Fri Sep 27 05:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864461, encodeId=f2f71864461bc, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri May 23 20:05:00 CST 2014, time=2014-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827585, encodeId=606d182e58558, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Jan 20 14:05:00 CST 2014, time=2014-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472420, encodeId=dbd114e242054, content=<a href='/topic/show?id=ba4a6436107' target=_blank style='color:#2F92EE;'>#污染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64361, encryptionId=ba4a6436107, topicName=污染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dfe67217539, createdName=小刀医生, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561550, encodeId=e92e15615506d, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567559, encodeId=2f33156e5592e, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Jul 13 06:05:00 CST 2013, time=2013-07-13, status=1, ipAttribution=)]
    2013-07-13 liuxiaona

相关资讯

CCC:吸烟者饮食中砷摄入量过多更易导致肺癌

日本国立癌症研究中心5日发表的一项研究结果显示,长期食用海藻等含砷海鲜类食物吸烟男性,患肺癌的几率比不食用此类食物的吸烟男性高。而对不吸烟的男性来说,砷摄入量越多,患肺癌的几率反而越低。对此,该研究中心呼吁“要想防肺癌就先戒烟”。   该研究中心将目光集中在日常饮食中砷元素摄入量和患癌症的关系。通过针对9个府县90378名45-74岁的男女性之间长达1

Lung cancer:培美曲塞化疗不需要因补充叶酸而延迟

对于晚期非小细胞肺癌一线化疗失败后培美曲塞化疗是二线化疗的首选。然而化疗前补充叶酸和维生素 B12的最佳持续时间迄今还未确定。针对这种情况,来韩国成均馆大学医学院首尔三星医疗中心血液肿瘤科的Young Saing Kim博士等人进行了一项研究,研究结果发表于2013年5月14日的《肺癌》(Lung cancer)杂志上。作者发现第一周期培美曲塞治疗前补充维生素的持续时间与培美曲塞相关的毒性无关,提

J Thorac Dis:吴一龙等研究认为应对疑似肺癌患者活检原则进行权衡考量

PET/CT扫描结果 占位部针刺活检及肌内结节切除样本 支气管镜及右上肺叶切除样本 在2013年6月期的《胸科疾病杂志》(Journalof Thoracic Disease)上,发表了我国广东省人民医院吴一龙教授等人的一篇文章。该文对活检原则进行了重新审视。在临床实践中,可通过多种手段获取到疑似肺癌患者的活检样本。既往文献认为,为达到诊断目的

Ann Thorac Surg:术中冰冻切片在肺癌切除术中作用有限

非小细胞肺癌(NSCLC)切除后支气管残端阳性不利于患者的术后生存。为了确保R0 切除,胸外科医生通常采用术中冰冻切片分析支气管残端。然而,对于术中冰冻切片在非小细胞肺癌切除患者中是否应该常规应用,这方面的研究较少。针对这种情况,来美国佐治亚州亚特兰大市埃默里大学医学院普胸外科的Fernandez博士等人进行了一项研究,研究结果发表于2013年6月的《胸外科年鉴》(Ann Thorac Surg)

ADA 2013:ORIGIN研究揭示甘精胰岛素和二甲双胍不改变癌症发生风险

几项对理赔数据库的回顾性分析发现,胰岛素使用与癌症发生(CA)有关,二甲双胍可减少癌症发生。Louise Bordeleau博士在美国糖尿病学会2013年会上介绍了ORIGIN的研究结果,发现二甲双胍和甘精胰岛素对受试者的CA风险没有影响。 ORIGIN研究是一项国际性双盲随机2*2析因试验,对比在心血管(CV)风险较高的糖尿病前期或糖尿病(DM)患者中,甘精胰岛素(来得时)或标准治疗与omeg

ACIEE:针对非小细胞肺癌EGFRT790M突变体的靶向化合物被设计

7月5日,记者在中科院广州生物医药与健康研究院获悉,该院科学家在克服非小细胞肺癌耐药研究方面获得新突破。相关结果在美国《药物化学杂志》和德国《应用化学》上在线发表。 肺癌是严重威胁人类健康的重大疾病,非小细胞肺癌则占所有类型肺癌的85%以上。目前,表皮生长因子(EGFR)受体抑制剂易瑞沙(吉非替尼)和特罗凯(埃罗替尼)等已在临床治疗非小细胞肺癌中获得巨大成功,但其耐药问题也日益突出。第二